EUCTR2009-009696-34-DE进行中（未招募）不适用
A Phase 2 Dose-Ranging Study of Multiple Subcutaneous Doses of LY2439821 (an Anti-IL-17 Antibody) in Patients with Active Rheumatoid Arthritis on Concomitant DMARD Therapy
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 648
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion Criteria Common to Both Populations
- •[1]Ambulatory males or females, 18 years to 75 years, inclusive.
- •[1a] Male patients:
- •Agree to use a reliable method of birth control during the study.
- •[1b] Female patients:
- •Are women of childbearing potential who test negative for
- •pregnancy and agree to use a reliable method of birth control
- •during the study. Methods of contraception considered
- •acceptable are oral contraceptives, contraceptive patch,
- •intrauterine device, vaginal ring, diaphragm, or condom with
- •contraceptive gel.
- •Are women who have undergone surgical sterilization
- •(hysterectomy, bilateral oophorectomy, or tubal ligation).
- •Are post menopausal female patients defined as women
- •>45 years of age who have had a cessation of menses for at least
- •12 months OR are women between 40 and 45 years of age who
- •test negative for pregnancy, have had a cessation of menses for at
- •least 12 months, and have a Follicle Stimulating Hormone (FSH)
- •value >40 mIU/mL.
- •[2]RA diagnosis by American Rheumatism Association 1987 Revised Criteria.
- •[4]At least 6 tender and at least 6 swollen joints.
- •[5]C-reactive protein (CRP) >ULN or erythrocyte sedimentation rate (ESR) of at least 28 mm/hr.
- •Inclusion Criterion Specific to the bDMARD-naive Population
- •[6]Regular use of MTX for at least 12 weeks, and stable treatment (7.5 mg/week to 25 mg/week) for at least 8 weeks prior to baseline.
- •Inclusion Criterion Specific to the TNFa-IR Population
- •[7]TNFa-IR patients must have been treated at approved doses with at least 1 biologic TNFa inhibitor therapy and in the opinion of the investigator EITHER: a) had an insufficient response to at least 3 months of treatment (stopped due to insufficient efficacy), OR b) have been intolerant of such treatment, regardless of treatment duration.
- •[8] Regular use of at least 1 conventional DMARD in a stable treatment regimen as specified.
- •Some of the included criteria have been condensed from protocol language. Refer to protocol pages 39-40 for the full list and full text of all Inclusion/Exclusion Criteria.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 380
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 68
排除标准
- •Exclusion Criteria Specific to the bDMARD naive Population
- •[9]Have received any prior biologic DMARD therapy.
- •[10] Have had, in the opinion of the investigator, an inadequate response to
- •treatment with 5 or more conventional DMARDs (such as
- •leflunomide, azathioprine, cyclosporine, hydroxychloroquine, gold
- •salts, and sulfasalazine), prescribed alone or in combination, at
- •approved doses, for a minimum of 3 months.
- •[11] Use of DMARDs other than MTX, hydroxychloroquine, or
- •sulfasalazine (for example, gold salts, cyclosporine, azathioprine, or
- •any other immunosuppressives) in the 8 weeks prior to baseline.
- •[12]Use of leflunomide in the 12 weeks prior to baseline. Cholestyramine may be used to shorten the washout period from 12 to 4 weeks for leflunomide, if used according to standard protocol (Van Riel et al. 2004).
- •Exclusion Criteria Specific to the TNFa-IR Population
- •[13]Concurrent or recent use of any biologic DMARDs or biologic TNFa inhibitor therapies within specified washout periods.
- •Exclusion Criteria Common to Both Populations
- •[15]Concomitant use of NSAIDs in Part A, unless patient is on stable dose for at least 2 weeks prior to baseline.
- •[16]Parenteral glucocorticoid administered by intra-articular, intramuscular, or IV injection within 4 weeks of baseline, or for whom a parenteral injection of glucocorticosteroids is anticipated during the course of the study.
- •[17]Use of oral corticosteroids (at average daily doses of >10 mg/day of prednisone or its equivalent) or use of variable doses of oral corticosteroids within 4 weeks prior to baseline.
- •[18]Live vaccination within 12 weeks before baseline, or intend to have a live vaccination during the course of the study, or have participated in a vaccine clinical study within 12 weeks prior to baseline.
- •[19]Have a diagnosis of any systemic inflammatory condition other than RA, such as juvenile RA, seronegative spondyloarthropathy, Crohn’s disease, ulcerative colitis, psoriasis, or psoriatic arthritis.
- •[23] Have had lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease.
- •[24]Have findings, or a history of, clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders, which in the opinion of the investigator, place the patient at an unacceptable risk for participation in the study or of interfering with the interpretation of data.
- •[26]Serious bacterial infection within 3 months of entry, or a recent or ongoing infection that in the opinion of the investigator poses an unacceptable risk to participate in the study.
- •[27]Evidence or suspicion of active tuberculosis (TB) by medical history, physical examination, and/or chest radiograph or documentation of TB by a positive purified protein derivative (PPD) test.
- •Exceptions to this criterion include patients with latent TB, who have a documented treatment history with isoniazid (INH) for at least 6 months or a rifampicin-based regimen for at least 3 months; or patients who have received documented, completed, effective chemotherapy for active TB with no history of re-exposure since their treatment was completed; or patients with a history of BCG vaccination within the 10 years prior to baseline and who have a negative chest x-ray.
- •[28]Uncontr
研究者
相似试验
已完成
不适用
A Phase 2 Dose-Ranging Study of Multiple Subcutaneous Doses of LY2439821 (an Anti-IL-17 Antibody) in Patients With Active Rheumatoid Arthritis on Concomitant DMARD Therapy-M069M069PER-094-09ELI LILLY AND COMPANY,31
已完成
2 期
A Study in Patients With Rheumatoid ArthritisCTRI/2009/091/000777Eli Lilly372
进行中（未招募）
不适用
Phase 2, Dose-Ranging Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Active Rheumatoid Arthritis Despite Ongoing Methotrexate TherapyRheumatoid arthritisEUCTR2008-004894-16-PLEli Lilly and Company limited150
进行中（未招募）
不适用
Phase 2, Dose-Ranging Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Active Rheumatoid Arthritis Despite Ongoing Methotrexate TherapyRheumatoid arthritisEUCTR2008-004894-16-CZEli Lilly and Company limited150
进行中（未招募）
1 期
Phase 2, Dose-Ranging Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Active Rheumatoid Arthritis Despite Ongoing Methotrexate TherapyRheumatoid arthritisEUCTR2008-004894-16-HUEli Lilly and Company limited150